Please assess the completion status of the following clinical trial:

Trial Title: Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years.~* Cirrhotic liver demonstrated by typical liver dysmorphy on imaging and/or liver biopsy.~* HCC with at least one lesion measuring more than 1 cm in diameter with a single dynamic imaging technique (CT or MRI), showing intense arterial uptake followed by washout of contrast in the venous-delayed phases, or diagnosed by biopsy.~* Borderline resectable disease eligible for surgical resection or radiofrequency destruction.~* No extra-hepatic dissemination.~* ECOG Performance status \< 2.~* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~* Signed written informed consent (approved by an Independent Ethics Committee) obtained prior to any study specific baseline procedures.~Exclusion Criteria:~* Decompensated cirrhosis (Child Pugh B, C).~* Extra-hepatic tumour spread.~* Previous or concomitant malignancies within five years other than basal cell carcinoma of the skin.~* Pregnancy, lactation or refusal to use adequate contraceptive measures (hormonal or barrier method of birth control, abstinence).~* Pre-existing other hepatic disease (liver abscess, hepatic sarcoidosis or tuberculosis, sclerosing cholangitis, ...).~* Previous trans-arterial radioembolization (TARE).~* History of allergic reactions attributed to compounds of similar chemical or biologic composition of the administered materials.~* Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular incident within the last six months.~* Major surgery within four weeks.~* Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Uncontrolled Diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preoperative aTARE (Type: EXPERIMENTAL): The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).